| Followers | 0 |
| Posts | 36 |
| Boards Moderated | 0 |
| Alias Born | 03/02/2006 |
Monday, June 26, 2006 4:01:11 PM
Rfoable and DoDD
I think we're all in agreement about TRCA's stats. Have you any thoughts about their other numbers, to which I'd alluded earlier.
To wit, TRCA claims 151 patients.
Assuming 27,000 $ per patient, that = $4.077 million.
Per quarter, it = $1.02 million.
Now they didn't have all of those patients for the entire quarter, so let's conservatively assume that the mean patient was enrolled for half the quarter.
Then they should have quarterly revenues along the lines of $510,000 when they report in August or so.
What gets me is that they only had revenues of $85,000 for the first quarter, despite reporting (in the most recent press release) that they had 61 patients then (which should give $206,000 revenues based on calculations above).
Is it possible that they are including patients enrolled in studies (for which I assume no revenues are received) in the total number of patients enrolled on Increlex? I don't mean to cast aspersions on their PR announcements, I just can't see any other way of getting these numbers without having huge numbers of patients enroll just before the quarter ends.
Thanks for letting me rant.
GS
I think we're all in agreement about TRCA's stats. Have you any thoughts about their other numbers, to which I'd alluded earlier.
To wit, TRCA claims 151 patients.
Assuming 27,000 $ per patient, that = $4.077 million.
Per quarter, it = $1.02 million.
Now they didn't have all of those patients for the entire quarter, so let's conservatively assume that the mean patient was enrolled for half the quarter.
Then they should have quarterly revenues along the lines of $510,000 when they report in August or so.
What gets me is that they only had revenues of $85,000 for the first quarter, despite reporting (in the most recent press release) that they had 61 patients then (which should give $206,000 revenues based on calculations above).
Is it possible that they are including patients enrolled in studies (for which I assume no revenues are received) in the total number of patients enrolled on Increlex? I don't mean to cast aspersions on their PR announcements, I just can't see any other way of getting these numbers without having huge numbers of patients enroll just before the quarter ends.
Thanks for letting me rant.
GS
Recent INSM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/17/2026 08:43:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/16/2026 08:17:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:41:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 08:01:21 PM
- Insmed Provides Clinical Update on Phase 2b CEDAR Study • PR Newswire (US) • 04/07/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 08:42:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:07:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 09:10:46 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/01/2026 08:03:54 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:02:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:01:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/31/2026 08:13:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/30/2026 09:31:03 PM
- Insmed shares rise after UTHR trial data and Morgan Stanley upgrade • IH Market News • 03/30/2026 03:04:13 PM
- Insmed shares rise on positive results from ARIKAYCE Phase 3b study • IH Market News • 03/23/2026 02:34:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:00:30 AM
- Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease • PR Newswire (US) • 03/23/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:05:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/19/2026 08:57:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:59:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:16:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:15:10 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 03/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 09:14:51 PM
